'It's magic stuff': The experiences of patients with ankylosing spondylitis taking anti-TNF-alpha medication

Musculoskeletal Care

Volumn 7, Issue 3, 2009, Pages 162-177

  Stockdale, J ^a   Goodacre, L ^b  

^a North Lancashire Teaching Primary Care Trust   (United Kingdom)

^b UNIVERSITY OF CENTRAL LANCASHIRE   (United Kingdom)

Author keywords

Ankylosing spondylitis; Anti TNF ; Medication; Quality of life

Indexed keywords

ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; DRUG ANTAGONISM; HOSPITALIZATION; HUMAN; MALE; MIDDLE AGED; PATHOPHYSIOLOGY; PATIENT SATISFACTION; QUALITY OF LIFE; REMISSION; SICKNESS IMPACT PROFILE; TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; HUMANS; MALE; MIDDLE AGED; PATIENT SATISFACTION; QUALITY OF LIFE; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 70349435731     PISSN: 14782189     EISSN: 15570681     Source Type: Journal    
DOI: 10.1002/msc.146     Document Type: Article

References (42)

1. Baraliakos X, Davis J, Tsuji W, Braun J (2005). Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumour necrosis factor alpha receptor fusion protein etanercept. Arthritis and Rheumatism 52(4): 1216-23.
2. Barlow J, Wright C, William B, Keta A (2001). Work disability among people with ankylosing spondylitis. Arthritis Care and Research 45(5): 424-9.
3. Barlow J, Macey S, Struthes G (1993). Gender and depression and ankylosing spondylitis. Arthritis Care and Research 6(1): 45-51.
4. Berkanovic E, Hurwiez M, Lachenbruch P (1995). Concordant and discrepant views of patients' physical functioning. Arthritis Care and Research 8(2): 94-101.
5. Boonen A, Chorus A, Miedema H, van der Heijde D, van der Tempel H, van der Linden S (2001a). Employment, work disability and work days lost in patients with ankylosing spondylitis: A cross sectional study of Dutch patients. Annals of the Rheumatic Diseases 60(4): 352-8.
6. Boonen A, Chorys A, Miedema H, van der Heijde D, Landewe R, Schouten H, van der Tempei H, van der Linden S (2001b). Withdrawal from labour force due to work disability in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases 60(11): 1033-9.
7. Brandt J, Khariouzov A, Listing J, Haibel H, Sorenson H, Grassnickel L, Rudwaleit M, Sieper J, Braun J (2004). Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis and Rheumatism 50(7): 2376-7.
8. Braun J, Brandt J, Listing J, Zink A, Alten R, Golder W, Gromnicalhle E, Kellner H, Krause A, Schneider M, Sorenson H, Zeilder H, Threie W, Sieper J (2002). Treatment of active ankylosing spondylitis with infliximab: A randomised controlled multicentre trial. Lancet 359(9313): 1187-93.
9. Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D, for the ASAS Working Group (2003). International ASAS consensus statement for the use of antitumour necrosis factor agents in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases 62(9): 817-24.
10. Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester R, Gromnicalhle E, Kellner H, Krause A, Schneider M, Sorenson H, Zeilder H, Sieper J (2005a). Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Annals of the Rheumatic Diseases 64(2): 229-34.
11. Braun J, Baraliakos X, Brandt J, Listing J, Zink A, Alten R, Burmester G, Gromnica-Ihle E, Kellner H, Schneider M, Sörensen H, Zeidler H, Sieper J (2005b). Persistent clinical response to the anti-TNF antibody infliximab in patients with ankylosing spondylitis over three years. Rheumatology 44(5): 670-6.
12. Braun J, Davis J, Dougados M, Sieper J, van der Linden S, van der Heijde D, for the ASAS Working Group (2006). First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Annals of the Rheumatic Diseases 65(3): 316-20.
13. British Society of Rheumatology (2004). BSR Guidelines for Prescribing TNFa Blockers in Adults with Ankylosing Spondylitis. Available at http://www.rheumatology.org.uk/guidelines/clinicalguidelines [Accessed 8 April 2006].
14. Calin A, Garrett S, Whitelock H, Kennedy LG, O'Hea J, Mallorie P, Jenkinson T (1994). A new approach to defining functional ability in ankylosing spondylitis: The development of the Bath Ankylosing Spondylitis Functional Index (BASFI). Journal of Rheumatology 21(12): 2281-5.
15. Calin A, Dijkmans B, Emery P, Hakala M, Kalden J, Leirisalo-Repo M, Mola E, Savarani C, Sanmarti R, Sany J, Sibilis J, Sieper J, van der Linden S, Veys E, Appel A, Faenejad S (2004). Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Annals of the Rheumatic Diseases 63(12): 1594-600.
16. Carr A, Gibson B, Robinson P (2001). Is quality of life determined by expectation or experience? British Medical Journal 322(7323): 1240-3.
17. Carr A, Thompson P (1994). Towards a measure of patient-perceived handicap in rheumatoid arthritis. British Journal of Rheumatology 33(4): 378-82.
18. Davis JC, van der Heijde D, Dougados M, Woolley JM (2005). Reductions in health-related quality of life in patients with ankylosing spondylitis and improvements with etanercept therapy. Arthritis Rheumatism 53(4): 494-501.
19. Doward LC, Spoorenberg A, Cook SA, Whalley D, Helliwell PS, Kay LJ, McKenna SP, Tennant A, van der Heijde,D, Chamberlain MA (2003) Development of the ASQoL: A quality of life instrument specific to ankylosing spondylitis. Annals of the Rheumatic Diseases 62(1): 20-6.
20. Engel G (1977). The need for a new medical model: A challenge for biomedicine. Science 196(4286): 129-136.
21. Garratt A, Schmidt L, Mackintosh A, Fitzpatrick R (2002). Quality of life measurement: Bibliographic study of patient assessed health outcome measures. British Medical Journal 324(7351): 1417.
22. Garret S, Jenkinson T, Kennedy L, Whitelock H, Gaisford P, Calin A (1994). A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). Journal of Rheumatology 21(12): 2286-91.
23. Goodacre L, Goodacre J (2004). Factors influencing the beliefs of patients with rheumatoid arthritis regarding disease modifying medication. Rheumatology 43(5): 583-6.
24. Gorman J, Sack K, Davis J (2002). Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. New England Journal of Medicine 346(18): 1349-56.
25. Hewlett S, Smith A, Kirwan J (2001). Values for function in rheumatoid arthritis: Patients, professionals and public. Annals of Rheumatic Diseases 60(10): 928-33.
26. Hewlett S (2003). Patients and clinicians have different perspective on outcomes in arthritis. Journal of Rheumatology 30(4): 877-9.
27. Jenkinson TR, Mallorie PA, Whitelock HC, Kennedy LG, Garrett SL, Calin A (1994). Defining spinal mobility in ankylosing spondylitis (AS): The Bath AS Metrology Index. Journal of Rheumatology 21(12): 1694-8.
28. Kwoh C, O'Connor G, Regan-Smith M, Olmstead EM, Brown LA, Burnett JB, Hochman RF, King K, Morgan GJ (1992). Concordance between patient and physician assessment of physical and mental health status. Journal of Rheumatology 19(7): 1031-7.
29. Marzo-Ortega H, McGonagle D, Jarrett S, Haugeberg G, Hensor E, Tan AL, Conaghan PG, Greenstein A, Emery P (2005). Infliximab in combination with methotrexate in active ankylosing spondylitis: A clinical and imaging study. Annals of the Rheumatic Diseases 64(11): 1568-75.
30. Mayo Clinic (2005). Etanercept (systemic). Available at http://www.mayoclinic.com [Accessed 24 May 2007].
31. Newman S, Mulligan K (2000). The psychology of rheumatic diseases. Bailliere's Best Practice and Research in Clinical Rheumatology 14(4): 773-86.
32. National Institute for Health and Clinical Excellence (2008). Adalimumab, etanercept and infliximab for ankylosing spondylitis. NICE technology appraisal 143. National Institute for Health and Clinical Excellence.
33. Nikas SN, Alamanos Y, Voulgari PV, Pliakou XI, Papadopoulos CG, Drosos AA (2005). Infliximab treatment in ankylosing spondylitis: An observational study. Annals of the Rheumatic Diseases 64(6): 940-2.
34. Ozgul A, Peker F, Taskaynatan MA, Tan AK, Dincer K, Kalyon TA (2006). Effects of ankylosing spondylitis on health-related quality and different aspects of social life in young patients. Clinical Rheumatology 25(2): 168-74.
35. Pincus T, Summey J, Soraci S, Wallston K, Jr, Hummon N (1983). Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. Arthritis and Rheumatism 26(11): 1346-53.
36. Polit DF, Hungler BP (1997). Nursing Research: Methods, Appraisal and Utilization (4th edn). Philidelphia, PA: Lippincroft-Raven Publishers.
37. Ritchie J, Lewis J (2003). Qualitative Research Practice: A Guide for Social Science Students and Researchers. London. Sage Publications.
38. Rosenbaum JK (2004). Effect of etanercept on iritis in patients with ankylosing spondylitis. Arthritis and Rheumatism 50(11): 3736-7.
39. van der Heijde D, Dijkmans D, Geusens P, Sieper J, DeWoody K, Williamson P, Braun J (2005). Efficacy and safety of infliximab in patients with ankylosing spondylitis: Results of a randomized, placebo-controlled trial. Arthritis and Rheumatism 52(2): 582-672.
40. van Manen M (1990). Researching Lived Experience: Human Science for an Action Sensitive Pedagogy. New York, NY: State University of New York Press.
41. Ward MM (1998). Quality of life in patients with ankylosing spondylitis. Rheumatic Diseases Clinics of North America 24(4): 815-27.
42. Zink A, Braun J, Listing J, Wollenhaupt J (2000). Disability and handicap in rheumatoid arthritis and ankylosing spondylitis: Results from the German rheumatological database. German Collaborative Arthritis Centers. Journal of Rheumatology 27(3): 613-22.